Introduction {#JVEv4-sec-0005}
============

Chronic hepatitis C virus infection (HCV) is a leading cause of chronic liver disease and the commonest indication for liver transplantation in Australia [@JVEv4-bib-0001]. In 2015, there were 800 deaths attributable to the disease in Australia, and it was estimated that 227,000 people were living with HCV; approximately 17,000 had cirrhosis [@JVEv4-bib-0002].

In Queensland, Australia\'s second-largest state, half the state\'s population reside in regional areas and have limited access to both primary and specialist care [@JVEv4-bib-0003]. To eradicate HCV, health services must overcome the challenges of delivering care to these regional and remote areas, as this has previously limited HCV treatment uptake [@JVEv4-bib-0005].

The safety and efficacy of direct-acting antivirals (DAAs) has heralded a new era of HCV treatment [@JVEv4-bib-0006]. DAAs were subsidised on the Pharmaceutical Benefit Scheme from March 2016, facilitating access. Further barriers to treatment were removed when the Pharmaceutical Benefits Advisory Committee recommended that DAAs could be prescribed by any medical practitioner experienced in treatment of HCV, or working in consultation with an appropriate specialist or nurse practitioner [@JVEv4-bib-0007]. This had the potential to improve access to HCV treatment in regional and remote centres significantly.

This study describes a decentralised model of DAA treatment delivery to a culturally diverse population in a regional Australian population with limited access to specialist care, and the associated treatment outcomes.

Methods {#JVEv4-sec-0006}
=======

This is a prospective cohort study of patients in regional Australia with HCV infection and receiving treatment with DAAs between 1 February 2016 and 31 December 2017. Patients were identified by referral to, or discussion with, the Cairns and Hinterland Hospital and Health Service located in Far North Queensland, Australia. Far North Queensland has a geographic area of 380,748 km^2^, and a population of approximately 280,000, 9% of whom identify as Aboriginal and/or Torres Strait Islanders [@JVEv4-bib-0008].

Patient demographics (age, gender, indigenous status) were collected to accurately describe the population characteristics. Clinical data (HCV viral load, HCV genotype, presence of cirrhosis and prior HCV treatment) were collected to analyse outcomes and variables influencing differences in outcomes. The presence of cirrhosis was determined by ultrasound or transient elastography (defined as a value kPa ≥12.5).

Data were entered into an electronic database (Microsoft Excel, Washington, USA) and analysed using statistical software (SPSS, IBM Software, New York, USA). Differences between groups were analysed using the chi-squared test.

Ethical approval for the study was provided by the Human Research Ethics Committee of St Vincent\'s Hospital, Sydney. As the collected data were retrospective, aggregated and de-identified, a requirement for patient consent was waived. The study received no dedicated funding.

Model of care {#JVEv4-sec-0007}
-------------

Referrals were triaged by staff from the liver clinic, the sexual health service or the addiction medicine service.

Patients with decompensated cirrhosis, prior treatment, significant comorbidities or complex drug--drug interactions were seen in the liver clinic. The sexual health and addiction medicine services and general practitioners cared for their patients with uncomplicated disease. The provision of treatment in regional settings was facilitated through specialist visits to remote communities and the delivery of DAAs to these areas by outreach pharmacy services. A clinical nurse and sexual health physician visited the local prison regularly to educate health workers and to assess and treat patients [@JVEv4-bib-0009]. Patient care was facilitated by having dedicated clinical nurses or other staff collating required information or performing transient elastography prior to the patient seeing a prescriber.

General practitioners\' referrals of uncomplicated cases were managed by providing the referring clinician with a standardised document that provided guidance regarding the recommended treatment regimen and monitoring. Additional phone or email support was provided as required. Sessions to promote awareness and provide education on hepatitis C treatment were provided to primary health providers in an effort to increase the number of potential prescribers. These education sessions were facilitated by local gastroenterologists, general and sexual health physicians, and supported by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), as well as pharmaceutical companies.

Promoting awareness has been a key priority in reaching and treating patients with HCV. The Cairns Hospital Sexual Health Service launched a campaign 'Cairns Hep C Free by 2020' and has a local volunteer group called 'CHAT' (Cairns Hepatitis Action Team) that promotes awareness of hepatitis C treatment in the community. The campaign is staffed by two health promotion officers who visit and provide education and promote awareness to general practice clinics, needle exchange centres, addiction medicine support groups and homeless shelters. Public awareness has been further increased by advertising on highway billboards, on public buses and in local newspapers.

Results {#JVEv4-sec-0008}
=======

Over the 22-month study period, 734 consecutive patients were prescribed DAAs for HCV.

Approximately half (49%) of the cohort had treatment prescribed by general practitioners and non-gastroenterologist specialists (Figure [1](#JVEv4-fig-0001){ref-type="fig"}).

![Distribution of prescribers. ATODS: Alcohol, Tobacco and Other Dugs Service](jve-4-160-g001){#JVEv4-fig-0001}

The most common genotypes were genotype 1a (340/734, 46.3%), genotype 3 (294/734, 40.1%) and genotype 1b (59/734, 8%) (Figure [2](#JVEv4-fig-0002){ref-type="fig"})

![Distribution of genotype. GT: genotype](jve-4-160-g002){#JVEv4-fig-0002}

The most frequently prescribed DAA regimens were sofosbuvir/ledipasvir (371/734, 50.5%), sofosbuvir/daclatasvir (287/734, 39.1%) and sofosbuvir/ribavirin (29/734, 4.0%) (Figure [3](#JVEv4-fig-0003){ref-type="fig"}). No patients were prescribed interferon. Other treatment regimens included sofosbuvir/velpatasvir, elbasvir/grazoprevir, paritaprevir/ritonavir/ombitasvir/dasabuvir, glecaprevir/pibrentasvir and sofosbuvir/simeprevir. No patients ceased treatment due to adverse effects.

![Direct-acting antiviral regimen prescriptions. SOF/LDV: sofosbuvir/ledipasvir; SOF/DAC: sofosbuvir/daclatasvir; SOF/RBV: sofosbuvir/ribavirin; SOF/VEL: sofosbuvir/velpatasvir](jve-4-160-g003){#JVEv4-fig-0003}

The cohort was predominantly male (507/734, 69.1%) and the mean age was 51.3 (range 19--77) years. Thirty-nine patients (5.3%) identified as Aboriginal or Torres Strait Islander, while 1.6% (12/734) of the cohort did not provide information on indigenous status. Seventy-six patients (10.4%) were participating in an opioid substitution programme and 34 (4.6%) patients had used injectable drugs within the preceding 6 months; six (0.8%) patients had HIV co-infection.

SVR12 results were available for 612 (83.4%) patients. These patients had an SVR12 rate of 94%. Fifty patients (6.8%) were lost to follow-up and 72 (9.8%) patients were awaiting SVR12 testing at the time of the study\'s completion (Figure [4](#JVEv4-fig-0004){ref-type="fig"}).

![Patient prescriptions and outcomes. DAAs: direct-acting antivirals; SVR: sustained virological response at 12 weeks](jve-4-160-g004){#JVEv4-fig-0004}

Presence of cirrhosis (147/612, 24.1%) did not independently impact significantly on SVR12 rates (136/147 \[92.5%\] *vs* 440/465 \[94.6%\], *p*=0.34). Most cirrhotic patients were Child--Pugh A (92.1%) rather than Child--Pugh B (7.3%) or Child--Pugh C (0.6%).

Treatment-experienced patients (95/612, 18.3% of the cohort) were more likely to be non-responders compared to treatment-naïve patients (10/95 \[10.5%\] *vs* 26/517 \[5%\], *p*=0.04) (Figure [5](#JVEv4-fig-0005){ref-type="fig"}). The treatment-experienced patients included four patients who had failed DAA therapy (4/95, 4.2%); three (75%) of these four patients were non-responders to second-line DAA therapy.

![Rates (%) of sustained virological response at 12 weeks](jve-4-160-g005){#JVEv4-fig-0005}

Treatment outcomes were similar amongst gastroenterologists (SVR 283/306, 92.5%), general practitioners (SVR 152/161, 94.4%), sexual health physicians (SVR 104/106, 98.1%) and other prescribers (SVR 37/39, 94.9%).

Discussion {#JVEv4-sec-0009}
==========

This study demonstrates that HCV can be treated in a regional setting by non-specialist physicians with outcomes equivalent to those from published clinical trials [@JVEv4-bib-0010], with limited additional resources and funding. The multidisciplinary, decentralised approach used in this cohort was able to reach vulnerable populations in one of the most remote regions of Australia. This approach would be expected to decrease HCV-related morbidity and mortality and reduce transmission, increasing the likelihood of HCV elimination [@JVEv4-bib-0007].

The health service used several strategies to decentralise treatment to increase DAA uptake. Specific models of care provided access to treatment for marginalised populations, including persons who inject drugs and persons in correctional facilities, in a culturally appropriate manner. The fact that the patients\' existing health care workers were able to prescribe the DAA therapy permitted prescription of DAA therapy within an existing therapeutic relationship, improving engagement and treatment adherence [@JVEv4-bib-0012].

The current study demonstrates that with appropriate education and support, primary care providers can treat the vast majority of patients eligible for direct-acting antivirals and play an integral role in HCV treatment. Their role is likely to increase with the simplicity of new pan-genotypic regimens with shorter lengths of treatment. Primary care providers were empowered through education programmes and shared-care models to prescribe community-based treatment, enhancing their skill mix and job satisfaction [@JVEv4-bib-0014]. An additional benefit is that these providers, through their long-term involvement with the patients, are better able to manage other major comorbidities -- including alcohol consumption and obesity -- which affect liver and general health as much as, if not more than, HCV [@JVEv4-bib-0015]. Competent primary care prescribers also minimise the need for specialist referral, which can interrupt the cascade of care and delay therapy, and can also disadvantage patients averse to attending hospitals. These collaborative and multidisciplinary approaches are critical to achieving the goal of HCV elimination and are recognised in federal and state government strategies [@JVEv4-bib-0016], as well as other recently published real-world examples [@JVEv4-bib-0018]. They can foster collaborative care amongst clinicians and may be a model for other medical conditions or health issues [@JVEv4-bib-0019].

Dedicated nurse practitioners and clinical nurses can play an integral role with triaging, assessing, educating and coordinating DAA treatment of patients with HCV, thereby increasing the accessibility and throughput of services [@JVEv4-bib-0004]. Although our model did not allow for nurse prescribers, this strategy has been used elsewhere in treatment of HCV with similar cure rates to medical officers [@JVEv4-bib-0019].

Further specialist care was expanded by increasing tertiary clinic throughput in hospital clinic settings, and the delivery of specialist care to remote areas via outreach visits in a 'hub and spoke' manner [@JVEv4-bib-0003]. Gastroenterologist and other specialist-led treatment will continue to be important in managing patients with HCV who have cirrhosis, are treatment experienced, or who have complex care needs. However, this type of service does not have the capacity to treat every patient with HCV, particularly in remote centres. A decentralised model is necessary to ensure that all patients have access to this very safe, effective and well tolerated DAA therapy.

The experience from this study is in keeping with the growing body of evidence surrounding models of care for HCV treatment, and other health care in rural and remote Australia. These include integrated/shared-care models between specialists and general practitioners, outreach services (hub and spoke type delivery with periodic visiting specialists), use of telehealth services, nurse practitioner models and educational programmes [@JVEv4-bib-0005]. By using these strategies, this study\'s outcomes of HCV treatment are consistent with the high benchmark set in clinical trials and confirmed in recently published real-world experience [@JVEv4-bib-0010].

There are several weaknesses in this study. Data collection was incomplete, particularly because not all patients treated by general practitioners independent of Cairns and Hinterland Hospital and Health Service may have been captured. Even so, this study has demonstrated that a significant number of patients have been treated in primary care with excellent outcomes.

Strengths of this study include its prospective design, with relatively large and consecutive numbers capturing data from multiple models of care. Furthermore, although the North Queensland population is a relatively mobile one, we were able to access the vast majority of patient data.

Future studies might examine treatment strategies to access individuals who are continuing to transmit the infection, particularly those who continue to inject drugs. Although not captured in this study, data detailing country of birth and ethnicity could provide insights into the local epidemiology of the infection and the individuals who are and, as significantly, who are not accessing treatment. This might inform specific culturally appropriate strategies to reach these populations. It will be interesting to see whether similar or even better results can be achieved with new shorter regimens. It will also be important to optimise the therapy of patients who have failed DAA treatment, and special populations such as persons with chronic kidney disease [@JVEv4-bib-0024].

In conclusion, non-specialist prescribers can effectively and quickly treat large numbers of patients using a decentralised, multidisciplinary model of care that reaches geographically isolated, socially marginalised and other vulnerable patient populations. This has the potential to significantly reduce the burden of HCV-related disease and is an excellent model for other chronic health conditions affecting these populations.
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